Clinical Trial

A Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety Between Administration of BR2021 and BR2021-1

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 10, 2025 (before its estimated October 28, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical study is to compare and evaluate the pharmacokinetic characteristics and the safety between administration of BR2021 and BR2021-1 in patients with metastatic adenocarcinoma of the pancreas
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-05; most recent amendment 2025-04-08.
Trial Details
NCT Number NCT06867497
Lead Sponsor Boryung Pharmaceutical Co., Ltd
Conditions Metastatic Adenocarcinoma of the Pancreas
Enrollment 20 participants
Start Date 2025-02-24
Primary Completion 2025-10-28 (estimated)
Study Completion 2025-10-28 (estimated)
Updated on ClinicalTrials.gov 2025-04-10